Ford I I - OmicsDI

Show results for

Unknown (1798)
Transcriptomics (31)
Proteomics (23)
Genomics (7)
Metabolomics (3)
Other (2)

Organisms

Homo sapiens (26)
Mus musculus (9)
Drosophila melanogaster (3)
Rattus norvegicus (3)
Arabidopsis thaliana (2)
Candida albicans (2)
Saccharomyces cerevisiae (2)
Ruditapes philippinarum (1)
Arabidopsis halleri (1)
Brassica juncea (1)
Pan troglodytes (1)
Oryza sativa (1)
Bos taurus (1)
Chlamydomonas reinhardtii (1)
Danio rerio (1)
Escherichia coli (1)
Ixodes scapularis (1)
Perna canaliculus (1)

Organisms

Ruditapes philippinarum (1)
Mus musculus (1)

Repository

biostudies-arrayexpress (35)
pride (21)
GPMDB (2)
MassIVE (2)
MetaboLights (2)
ENA (2)
EGA (1)
GNPS (1)

Tissue

Cell culture (4)
HeLa cell (3)
Brain (2)
Whole body (2)
Blood plasma (1)
Cell suspension culture (1)
Embryonic stem cell (1)
Endothelium (1)
Epithelial cell of prostate (1)
Heart (1)
Microvascular endothelium (1)
Pancreas (1)
Photosynthetic cell (1)
Prostate adenocarcinoma cell line (1)
Regular cardiac myocyte (1)
Saliva-secreting gland (1)
Salivary gland (1)
Schwann cell (1)
T cell (1)

Disease

Wounds and Injuries (3)
T-cell acute lymphoblastic leukemia (2)
Not Available (2)
Normal (1)
Disease free (1)
Propionic acidemia (1)
Prostate carcinoma (1)

Technology Type

Mass Spectrometry (21)
Shotgun proteomics (10)
Bottom-up proteomics (7)
Data-independent acquisition (6)
Data-dependent acquisition (3)
Affinity purification coupled with mass spectrometry proteomics (2)
Gel-based experiment (2)
Mass spectrometry (1)
NMR spectroscopy (1)
SWATH MS (1)

Instrument Platform

Instrument (2)
Unix (1)
Illumina HiSeq 1500 (1)
Illumina HiSeq 2500 (1)
NextSeq 500 (1)
LCMS-IT-TOF (1)
Orbitrap Fusion ETD (1)
Q Exactive Plus (1)
Nuclear Magnetic Resonance (NMR) - (1)
Q Exactive (1)

Publication Date

2016 (8)
2015 (6)
2014 (5)
2012 (5)
2022 (4)
2013 (4)
2025 (4)
2026 (4)
2023 (4)
2021 (4)
2008 (2)
2005 (2)
2020 (2)
2017 (1)
2011 (1)
2004 (1)
2024 (1)
2019 (1)
2018 (1)

CHEBI ID

CHEBI:10072 (1)
CHEBI:111517 (1)
CHEBI:132188 (1)
CHEBI:132948 (1)
CHEBI:132966 (1)
CHEBI:132994 (1)
CHEBI:133005 (1)
CHEBI:133032 (1)
CHEBI:133066 (1)
CHEBI:133089 (1)
CHEBI:133119 (1)
CHEBI:133148 (1)
CHEBI:133172 (1)
CHEBI:133181 (1)
CHEBI:133183 (1)
CHEBI:133186 (1)
CHEBI:133206 (1)
CHEBI:133217 (1)
CHEBI:133226 (1)
CHEBI:133430 (1)
CHEBI:133435 (1)
CHEBI:133460 (1)
CHEBI:133504 (1)
CHEBI:133512 (1)
CHEBI:133532 (1)
CHEBI:133534 (1)
CHEBI:133559 (1)
CHEBI:133562 (1)
CHEBI:133565 (1)
CHEBI:133568 (1)

Metabolite Name

(R)-3-Hydroxybutyricacid (1)
(R)-3-hydroxybutyrylcarnitine (1)
1,3,7-trimethylurate (1)
1,7-dimethylurate (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* (1)
1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* (1)
1-methyl-4-imidazoleacetate (1)
1-methyladenine (1)
1-methyladenosine (1)
1-methylguanidine (1)
1-methylguanine (1)
1-methylhistamine (1)
1-methylhistidine (1)
1-methylnicotinamide (1)
1-methylxanthine (1)
1-oleoyl-2-linoleoyl-GPC (18:1/18:2)* (1)
1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) (1)
1-palmitoyl-2-oleoyl-GPC (16:0/18:1) (1)
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* (1)
1-palmitoyl-2-stearoyl-GPC (16:0/18:0) (1)
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) (1)
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) (1)
1-stearoyl-2-oleoyl-GPC (18:0/18:1) (1)
1-stearoyl-2-oleoyl-GPE (18:0/18:1) (1)
16a-hydroxy DHEA 3-sulfate (1)
2'-AMP (1)
2'-O-methylcytidine (1)
2'-O-methyluridine (1)
2'-deoxyadenosine (1)

First Public Date

2026 (1)
2015 (1)

Modification

1x(15)N labeled L-valine (1)

Study type

Transcription profiling by array (22)
RNA-seq of coding RNA (6)
ChIP-seq (3)
Unknown experiment type (1)
Comparative genomic hybridization by array (1)
Methylation profiling by array (1)
Methylation profiling by high throughput sequencing (1)

Release Date

2022 (219)
2021 (187)
2025 (179)
2023 (177)
2024 (158)
2019 (128)
2020 (110)
2018 (110)
2016 (92)
2015 (92)
2017 (90)
2014 (68)
2013 (50)
2012 (46)
2011 (35)
2010 (28)
2026 (24)
2009 (16)
2008 (15)
2005 (4)
2007 (2)
2004 (1)
2006 (1)
1998 (1)

Lab affiliation

MOBILion Systems, Inc. (2)
UCSD (2)
CRUK - Beatson Institute for Cancer Research - Switchback Rd, Bearsden, Glasgow G61 1BD - United Kingdom (1)
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (1)
Department of Medical Oncology and Department of Molecular Cancer Research, Cancer Genomics Netherlands, University Medical Center Utrecht, Utrecht, the Netherlands (1)
Department of Microbiology and Immunology University of Maryland School of Medicine USA (1)
Department of Neurology, Henry Ford Health (1)
Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA (1)
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK. (1)
Genetics, Genomics, and Systems Biology, The University of Chicago (1)
Head of The Steen-Laboratory, Director of Proteomics, Boston Children's Hospital, Harvard Medical School (1)
MOBILion Systems, Inc (1)
MOBILion Systems, Inc., US (1)
Parker Institute for Cancer Immunotherapy, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, South Pavilion Tower, Building 421, Rm 8-103 3400 Civic Center Blvd. Philadelphia, PA 19104-5157 (1)
Plant and Food Research Institute New Zealand (1)
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. (1)
School of Pharmacy, University of Wisconsin-Madison (1)
Stanford University Department of Chemical and Systems Biology (1)
University of Oxford (1)

Tags

xref:PubMed:25555813 (1)

Previous page
1 / 187
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 187
Next page

Sort by:

Relevance

Page size

Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.

Not available

S-EPMC10088621 | biostudies-literature

The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins

PRJNA1251359 | ENA

Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer.

Not available

S-EPMC7851493 | biostudies-literature

Serum metabolomics identifies unique inflammatory signatures to distinguish rheumatoid arthritis responders and non-responders to TNF inhibitor therapy

Rheumatoid arthritis (RA) is an auto-immune disease which causes irreversible damage to tissue and cartilage within synovial joints. Rapid diagnosis and treatment with disease-modifying therapies is essential to reduce inflammation and prevent destruction of the joint. RA is a heterogeneous disease,...

2025-08-14 | MTBLS6213 | MetaboLights

Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer.

Not available

S-EPMC6661574 | biostudies-literature

KRAS Epitope Identification Immunopeptidomics

Utilizing computational epitope prediction and biochemical assays we predicted and identified high-affinity and/or high-stability KRAS peptides to high prevalence HLA class I molecules. Using single HLA class I allele lines and tumor cell lines in conjunction with MS spectrometry, selected mKRAS epi...

ORGANISM(S): Homo sapiens (Human)

2021-05-29 | PXD024412 | Pride